Literature DB >> 22039037

Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Shouwei Li1, Changxiang Yan, Lei Huang, Xiaoguang Qiu, Zhongcheng Wang, Tao Jiang.   

Abstract

The increased chemosensitivity of oligodendroglial tumors has been associated with loss of heterozygosity (LOH) on chromosomes 1p and 19q. Other clinical and molecular factors have also been identified as being prognostic and predictive for treatment outcome. Seventy-seven patients with anaplastic oligodendroglioma (AO) or anaplastic oligoastrocytoma (AOA), treated in Beijing Tiantan Hospital from 2006 through 2008, were reviewed. LOH 1p, LOH 19q, IDH1 mutation, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and protein expression level of MGMT, P53, EGFR, and Ki-67 were evaluated. Age at diagnosis, LOH 1p and 19q, IDH1 mutation, P53 expression level, reoperation when progression, and adjuvant chemotherapy were statistically significant factors for overall survival (OS) in univariate analysis. Further multivariate analysis showed that age at diagnosis (P = .010), LOH 1p and 19q (P = .016), IDH1 mutation (P = .011), and reoperation after progression (P = .048) were independent predictors for longer survival in these patients. Nonrandom associations were found between LOH 1p and LOH 19q, MGMT promoter methylation and LOH 1p or 19q, IDH1 mutation and LOH 1p and 19q, IDH1 mutation and MGMT promoter methylation, whereas mutual exclusion was found between MGMT promoter methylation and MGMT expression level. The present study confirmed that age at diagnosis, LOH 1p and 19q, IDH1 mutation, and reoperation after progression were independent significant prognostic factors for patients with anaplastic oligodendroglial tumors. Inter-relationship between LOH 1p, LOH 19q, IDH1 mutation, MGMT promoter methylation, and MGMT expression level were also revealed. Future clinical trials for AO and AOA should consider the molecular alterations of patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22039037      PMCID: PMC3245998          DOI: 10.1093/neuonc/nor185

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  29 in total

Review 1.  Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients.

Authors:  Liu-song Yang; Feng-ping Huang; Kang Zheng; Hai-shi Zhang; Xiang Zhou; Xu-hui Bao; Jia-jun Zheng; Chuan Chang; Liang-fu Zhou
Journal:  J Neurooncol       Date:  2010-02-27       Impact factor: 4.130

2.  Determination of loss of heterozygosity in frozen and paraffin embedded tumors by denaturating high-performance liquid chromatography (DHPLC).

Authors:  E Kleymenova; C L Walker
Journal:  J Biochem Biophys Methods       Date:  2001-01-30

3.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

4.  Anaplastic oligodendroglioma.

Authors:  Jaishri Blakeley; Stuart Grossman
Journal:  Curr Treat Options Neurol       Date:  2008-07       Impact factor: 3.598

5.  Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas.

Authors:  Tahsin Yakut; Angelika Gutenberg; Ahmet Bekar; Unal Egeli; Bastian Gunawan; Ilker Ercan; Sahsene Tolunay; Muammer Doygun; Hans-Jurgen Schulten
Journal:  Oncol Rep       Date:  2007-05       Impact factor: 3.906

6.  Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors.

Authors:  L Huang; T Jiang; F Yuan; G L Li; E Z Liu; Z C Wang
Journal:  Clin Neurol Neurosurg       Date:  2008-10-08       Impact factor: 1.876

Review 7.  Chemotherapy of anaplastic oligodendroglial tumours.

Authors:  Riccardo Soffietti
Journal:  Expert Opin Pharmacother       Date:  2004-02       Impact factor: 3.889

8.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

9.  IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Yannick Marie; Alba A Brandes; Martin J B Taphoorn; Pieter Wesseling; Marc Frenay; Cees C Tijssen; Denis Lacombe; Ahmed Idbaih; Ronald van Marion; Johan M Kros; Winand N M Dinjens; Thierry Gorlia; Marc Sanson
Journal:  Clin Cancer Res       Date:  2010-02-16       Impact factor: 13.801

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  19 in total

1.  Overexpression of SLC7A7 predicts poor progression-free and overall survival in patients with glioblastoma.

Authors:  Songhua Fan; Delong Meng; Tao Xu; Yuanyuan Chen; Jingkun Wang; Xiaoying Li; Hongyan Chen; Daru Lu; Juxiang Chen; Qing Lan
Journal:  Med Oncol       Date:  2013-02-14       Impact factor: 3.064

2.  Loss of heterozygosity 1p/19q and survival in glioma: a meta-analysis.

Authors:  Jiaxin Zhao; Wenjie Ma; Hong Zhao
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

3.  Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas.

Authors:  Andrew L Lin; Jingxia Liu; John Evans; Eric C Leuthardt; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Albert H Kim; Gregory J Zipfel; Robert L Grubb; Jiayi Huang; Clifford G Robinson; Joseph R Simpson; Gerald P Linette; Michael R Chicoine; David D Tran
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

4.  Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution.

Authors:  Pei Yang; Yongzhi Wang; Xiaoxia Peng; Gan You; Wei Zhang; Wei Yan; Zhaoshi Bao; Yinyan Wang; Xiaoguang Qiu; Tao Jiang
Journal:  J Neurooncol       Date:  2013-03-13       Impact factor: 4.130

5.  Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis.

Authors:  Hairui Sun; Lianhu Yin; Showwei Li; Song Han; Guangrong Song; Ning Liu; Changxiang Yan
Journal:  J Neurooncol       Date:  2013-03-16       Impact factor: 4.130

6.  Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1.

Authors:  Sheng-Hua Chu; Zhang-Ming Zhou; Dong-Fu Feng; Yan-Bin Ma
Journal:  Mol Biol Rep       Date:  2013-12-27       Impact factor: 2.316

7.  Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.

Authors:  Pei Yang; Jinquan Cai; Wei Yan; Wei Zhang; Yinyan Wang; Baoshi Chen; Guilin Li; Shouwei Li; Chenxing Wu; Kun Yao; Wenbin Li; Xiaoxia Peng; Yongping You; Ling Chen; Chuanlu Jiang; Xiaoguang Qiu; Tao Jiang
Journal:  Neuro Oncol       Date:  2016-03-07       Impact factor: 13.029

8.  Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.

Authors:  Chuan-Bao Zhang; Zhao-Shi Bao; Hong-Jun Wang; Wei Yan; Yan-Wei Liu; Ming-Yang Li; Wei Zhang; Ling Chen; Tao Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-23       Impact factor: 4.322

9.  1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Authors:  Haihui Jiang; Xiaohui Ren; Xiangli Cui; Junmei Wang; Wenqing Jia; Zhiming Zhou; Song Lin
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 13.029

10.  Anaplastic oligodendroglioma: advances and treatment options.

Authors:  Mairéad G McNamara; Solmaz Sahebjam; Warren P Mason
Journal:  Curr Treat Options Neurol       Date:  2013-06       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.